Australia | Apr 20 2006
Shares of artificial heart device developer Ventracor (VCR) are slightly in retreat today, more or less in line with the broader market, so nothing to really get worried or excited about.
Reading ABN Amro Morgans’ latest update on the company, it would seem that investors have either become less reactive to seemingly negative news, or the real punters have simply left and abandoned since the shares fell from their high of $1.72 not that long ago. (Maybe nobody knows about this just yet).
The Center for Medicare and Medicaid Services (CMS) in the US, ABN Amro Morgans’ Scott Power reports, has proposed changes in reimbursement rates for hospital inpatient procedures.
While the changes seem to target so-called "reimbursement loopholes" used by specialty hospitals for devices such as pacemakers, defibrillators and stents, Power doesn’t think they will have any noteworthy impact on future sales of Ventracor devices in the US market.
He does note some US based heart device companies such as J&J, St Jude and Boston Scientific saw their share prices weaken overnight in response to the news, but as far as Ventracor is concerned, no material impact is expected.
Power says he remains confident he won’t have to change his twelve month price target for the shares. His target currently stands at $1.70, suggesting upside potential of 88.8% from its current price level. Just to add a little more confidence to the occasion: his target is derived from a DCF measured valuation, which is also $1.70.
ABN Amro Morgans recommendation is, of course, Buy.

